AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS - 2017 Issue 4; New/Revised ICD-10-PCS Procedure Codes
New Therapeutic Substances
Four new Substance values were added to code table XW0, Anatomical Regions, Introduction, as follows: Device/Substance/TechnologyA Bezlotoxumab Monoclonal Antibody B Cytarine and Daunorubicin Liposome Antineoplastic C Engineered Autologous Chimeric Antigen Receptor T-Cell Immunotherapy F Other New Technology Therapeutic Substance Bezlotoxumab Bezlotoxumab, also known by its brand name ZINPLAVA, is used to treat patients who are already receiving an antibiotic for Clostridium difficile infection but who are at high risk for recurrence. Rather than targeting the Clostridium difficile bacteria itself as the antibiotic does, Bezlotoxumab is a monoclonal antibody that targets toxins produced by the Clostridium difficile bacteria, and...
Subscribe or sign in to view the full article.
Article Overview
This article covers a coding update tied to ICD-10-PCS table XW0 and describes several newly added substance values associated with newer therapies. It is intended for coding professionals who need to understand the scope of the update, the clinical areas affected, and the general type of substance-related guidance discussed in the article.
Why This Topic Matters
Updates involving new therapeutic substances can affect how inpatient procedures and related drug administrations are represented in coding systems. This article helps readers identify the affected table, the kinds of therapies referenced, and the broader clinical contexts involved.
Article Sections
-
New Substance Values Added to XW0
Introduces the update to the ICD-10-PCS XW0 table and lists the newly added substance values. It provides the general framework for the therapeutic substance changes discussed in the article.
-
Bezlotoxumab
Describes a newer monoclonal antibody therapy and its general clinical use. The section places the substance in the context of infection management and intravenous administration.
-
Cytarabine and Daunorubicin
Summarizes a combined oncology formulation and its relationship to chemotherapy treatment. It covers the broad clinical setting and administration route associated with the therapy.
-
Engineered Autologous Chimeric Antigen Receptor T-Cell Immunotherapy
Reviews a cell-based immunotherapy used in hematologic oncology. The section describes the therapy at a high level and its relevance to advanced treatment settings.
-
Other New Technology Therapeutic Substances
Explains the additional table value added for certain new technology intravenous drugs when no more specific code exists. It focuses on the general applicability of the new value within the table.
What You Will Learn
- What ICD-10-PCS table update is discussed
- Which general therapeutic substances are newly referenced
- What clinical settings the therapies are associated with
- How the article frames the addition of a broader new-technology substance value
- Which specialties are most likely to encounter the update
Who Should Read This
- Inpatient coding professionals
- ICD-10-PCS coders
- Clinical coding educators
- Health information management staff
- Oncology coding teams
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com